The need to improve diversity among clinical trial participants has been recognized for some time now, but the issue gained prominence during the COVID-19 pandemic when discussions around inequitable access to research and treatments became more pronounced.
Global Regulator Action To Improve Diversity In Clinical Trials
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
